Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
Key Highlights
- ➤Annovis will present clinical programs and upcoming milestones at U.S. Biotech Day November 16.
- ➤CEO Maria Maccecchini will present buntanetap’s clinical progress at Pharma Partnering Summit November 19.
- ➤Annovis will hold one-on-one meetings with biotech and pharma representatives during both events.
- ➤Buntanetap is an investigational Phase 3 oral therapy targeting Alzheimer’s and Parkinson’s diseases.
Expert Statements
Maria Maccecchini, Founder, President and CEO of Annovis Bio
“Bridging the Translational Gap: From Discovery Insights to Clinical Proof”
MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, PhD, Founder, President and CEO of Annovis, will participate and present in two industry events in November.
U.S. Biotech Day 2026 | November 16–17, 2026 | Philadelphia, PA * Panel: “Bridging the Translational Gap: From Discovery Insights to Clinical Proof”, November 16, 9:15–9:45 a.m. ET * Company showcase: November 16, 10:15–10:30 a.m. ET At U.S. Biotech Day 2026, Dr. Maccecchini will join a panel of leaders from Pfizer, Merck, Bristol Myers Squibb, Boehringer Ingelheim and other pharmaceutical companies to discuss how discovery-stage insights translate into clinical proof. She will also deliver a company presentation highlighting Annovis’ clinical programs and upcoming milestones.
Get started
Create a free account to read the full story.